A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS (=16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES

CB BIOSCIENCES, INC.0 个研究点目标入组 900 人开始时间: 2011年4月26日最近更新: 2014年8月28日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 900

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1 An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written informed consent form is signed and dated by the subject or by the parent(s) or legal representative. The consent form or a specific assent form, where required, will be signed and dated by minors
•2 Subject/legal representative is considered reliable and capable of adhering to the protocol (eg, able to understand and complete diaries), visit schedule, or medication intake according to the judgment of the Investigator
•3 Subjects (male or female) from 16 to 80 years, both inclusive. Subjects under 18 years may only be included where legally permitted and ethically accepted
•4 Subjects with a body weight =40kg
•5 Female subjects without childbearing potential (premenarcheal, postmenopausal for at least 2 years, bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible. Female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method. Oral or depot contraceptive treatment with at least 30µg ethinylestradiol per intake [or 50µg ethinylestradiol per intake if associated with any strong enzyme inducer (eg carbamazepine, phenobarbital, primidone, phenytoin, oxcarbazepine, St. John’s Wort, rifampicin)], monogamous relationship with vasectomized partner, or double-barrier contraception are acceptable methods. The subject must understand the consequences and potential risks of inadequately protected sexual activity, be educated about and understand the proper use of contraceptive methods, and undertake to inform the Investigator of any potential change in status. Abstinence will be considered as an acceptable method of contraception if the Investigator can document that the subject agrees to be compliant
•6 Well-characterized focal epilepsy/epileptic syndrome according to the 1989 International League Against Epilepsy (ILAE) classification
•7 Presence of an EEG reading compatible with the clinical diagnosis of focal epilepsy within the last 5 years
•8 Presence of a brain MRI/computed tomography (CT) scan performed within the last 2 years
•9 Subjects having at least 8 Type I seizures [POS; focal seizures (according to the 1981 ILAE classification)] during the 8-week Baseline Period with at least 2 Type I seizures during each 4-week interval of the Baseline Period
•10 Subjects having at least 2 partial onset seizures whether or not secondarily generalized per month during the 3 months preceding V1
•11 Subjects being uncontrolled while treated by 1 or 2 permitted concomitant AED(s). Vagal Nerve Stimulation (VNS) is allowed and will be counted as a concomitant AED
•12 Permitted concomitant AED(s) and VNS being stable and at optimal dosage for the subject from at least 1 month (3 months for phenobarbital, phenytoin, and primidone) before V1 and expected to be kept stable during the Baseline and Treatment Period. Benzodiazepine taken more than once a week (for any indication) will be considered as a concomitant AED
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 5
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 35
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 5

排除标准

•1 Subject previously randomized within this study or any other prior study with BRV as a dosing arm
•2 Seizure type IA (1981 ILAE classification) nonmotor as only seizure type
•3 Subject has participated in another study of an investigational medication (or a medical device) within the last 30 days or is currently participating in another study of an investigational medication (or a medical device)
•4 Subject is currently treated with LEV
•5 Subject has taken LEV within 90 days prior to V1
•6 Subject has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject’s ability to participate in this study
•7 Subject has a known hypersensitivity to any components of the investigational medicinal product or comparative drugs as stated in this protocol
•8 Subject not able to read and understand the informed consent form, assent form, or seizure diary card instructions
•9 Subject has obvious cognitive impairment or mental retardation as per Investigator assessment
•10 Subjects whose seizures could not be reliably counted on a regular basis due to their fast and repetitive occurrence (clusters or flurries)
•11 Subject has history or presence of status epilepticus during the year preceding V1 or during Baseline
•12 Subject has history or presence of known psychogenic nonepileptic seizures
•13 Subject on felbamate with less than 18 months exposure before V1
•14 Subject currently on vigabatrin. Subject with history of vigabatrin use but either no visual fields examination report available including standard static (Humphrey or Octopus) or kinetic perimetry (Goldman) or results of these examinations are abnormal
•15 Subject taking any drug with possible central nervous system (CNS) effects except if stable from at least 1 month before V1 and expected to be kept stable during the Treatment Period
•16 Subject taking any drug that may significantly influence the metabolism of BRV cytochrome P450 (potent inducers) except if the dose has been kept stable at least 1 month before V1, and is expected to be kept stable during the Treatment Period
•17 Subject has history of cerebrovascular accident, including transient ischemic attack, in the last 6 months
•18 Subject is suffering from severe cardiovascular disease or peripheral vascular disease
•19 Subject has presence of any sign (clinical or imaging techniques) suggesting rapidly progressing (ie, not expected to stay stable during study participation) brain disorder or brain tumor. Stable arteriovenous malformations, meningiomas, or other benign tumors may be acceptable.
•20 Subject has any clinical conditions (eg, bone marrow depression, chronic hepatic disease, and/or severe renal impairment) which impair reliable participation in the study or necessitate the use of medication not allowed by protocol
•21 Subject has presence of a terminal illness
•22 Subject has presence of a serious infection
•23 Subject has history of severe adverse hematologic reaction to any drug
•24 Subject is suffering from severe disturbance of hemostasis
•25 Subject has impaired hepatic function: ALT/SGPT (alanine aminotransferase/serum glutamic pyruvate transaminase), AST/SGOT (aspartate aminotransferase/serum glutamic oxaloacetic transaminase), alkaline phosphatase of more than 2 times the upper limit of the reference range
•26 Gamma-glutamyltransferase (GGT) values of more than 3 times the upper limit of the reference range. A result of GGT exceeding 3 times the upper limit can only

研究者

发起方

CB BIOSCIENCES, INC.

相似试验

进行中（未招募）

1 期

Tocilizumab plus background therapy versus placebo plus background therapy in patients with severe COVID-19 pneumonia.Severe COVID-19 pneumoniaMedDRA version: 21.1Level: PTClassification code 10035737Term: Pneumonia viralSystem Organ Class: 10021881 - Infections and infestations

EUCTR2020-001154-22-DKF. Hoffmann-La Roche Ltd450

进行中（未招募）

1 期

STUDY OF ECULIZUMAB IN RELAPSING NEUROMYELITIS OPTICA SUBJECTSeuromyelitis OpticaMedDRA version: 19.0Level: LLTClassification code 10029322Term: Neuromyelitis opticaSystem Organ Class: 100000004852

EUCTR2013-001150-10-GBAlexion Pharmaceuticals, Inc.143

进行中（未招募）

1 期

MP1032 Treatment in Patients with Moderate to Severe COVID-19Moderate to severe coronavirus disease 2019 (COVID 19)MedDRA version: 23.1Level: LLTClassification code 10084401Term: COVID-19 respiratory infectionSystem Organ Class: 100000004862MedDRA version: 23.1Level: PTClassification code 10084460Term: COVID-19 treatmentSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 23.0Level: LLTClassification code 10084382Term: Coronavirus disease 2019System Organ Class: 100000004862MedDRA version: 23.1Level: LLTClassification code 10084529Term: 2019 novel coronavirus infectionSystem Organ Class: 100000004862

EUCTR2021-000344-21-ROMetrioPharm AG120

进行中（未招募）

1 期

EUCTR2021-000344-21-FRMetrioPharm AG132

未知

不适用

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE III STUDY OF RAD001 ADJUVANT THERAPY IN POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF RAD001 VERSUS MATCHING PLACEBO AFTER PATIENTS HAVE ACHIEVED COMPLETE RESPONSE WITH FIRST-LINE RITUXIMAB-CHEMOTHERAPY

PER-087-11OVARTIS BIOSCIENSES PERU S.A.,